Marc Stapley

Marc Stapley is Chief Executive Officer of Veracyte, a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. He also serves on the company’s board of directors.

Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise building and leading complex global enterprises. Prior to joining Veracyte in June 2021, he was Chairman and CEO of Helix, a leading population genomics company, from April 2019 to May 2021. Under Mr. Stapley’s leadership, Helix built one of the largest COVID-19 testing labs in the United States and became a national leader in viral surveillance.

Prior to Helix, Mr. Stapley served in key executive leadership positions at Illumina, the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. At Illumina, he served as Chief Financial Officer, Chief Administrative Officer, and Executive Vice President over the course of seven years, where he led many functions including G&A, corporate strategy, business development, population genomics and government affairs.

Before joining Illumina, Mr. Stapley was Senior Vice President, Finance, at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts for key acquisitions and providing oversight to the company’s largest technology investment program. Prior to that he served in a variety of senior finance roles at Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand (now PwC). He currently serves as a member of the board of directors of Helix, and Glaukos.

Mr. Stapley holds a B.Sc. (Honors) in Mathematics from the University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.